Variable access to antiviral treatment of chronic hepatitis B in Canada: A descriptive study

Background: Antiviral treatment for chronic hepatitis B is costly, which presents challenges for universal drug coverage for the estimated 480 000 people with the disease in Canada. We appraised criteria for reimbursement of chronic hepatitis B antivirals by public drug plans in Canada.

Year of Publication: 2019

Authors: Stephen Congly, Mayur Brahmania

Journal Title: CMAJ Open